TY - JOUR
T1 - Radiotherapy with 4 Gy × 5 versus 3 Gy × 10 for metastatic epidural spinal cord compression: Final results of the SCORE-2 Trial (ARO 2009/01)
AU - Rades, Dirk
AU - Šegedin, Barbara
AU - Conde-Moreno, Antonio J.
AU - Garcia, Raquel
AU - Perpar, Ana
AU - Metz, Michaela
AU - Badakhshi, Harun
AU - Schreiber, Andreas
AU - Nitsche, Mirko
AU - Hipp, Peter
AU - Schulze, Wolfgang
AU - Adamietz, Irenaeus A.
AU - Norkus, Darius
AU - Rudat, Volker
AU - Cacicedo, Jon
AU - Schild, Steven E.
N1 - Publisher Copyright:
© 2016 by American Society of Clinical Oncology.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/2/20
Y1 - 2016/2/20
N2 - Purpose To compare short-course radiotherapy (RT) (4 Gy × 5) to longer-course RT (3 Gy × 10) for metastatic epidural spinal cord compression (MESCC). Patients and Methods Two-hundred three patients with MESCC and poor to intermediate expected survival were randomly assigned to 4 Gy × 5 in 1 week (n = 101) or 3 Gy × 10 in 2 weeks (n = 102). Patients were stratified according to ambulatory status, time developing motor deficits, and primary tumor type. Seventyeight and 77 patients, respectively, were evaluable for the primary end point, 1-month overall response regarding motor function defined as improvement or no further progression of motor deficits. Other study end points included ambulatory status, local progression-free survival, and overall survival. End points were evaluated immediately after RT and at 1, 3, and 6 months thereafter. Results At 1 month, overall response rates regarding motor function were 87.2% after 4 Gy × 5 and 89.6% after 3 Gy × 10 (P = .73). Improvement rates were 38.5% and 44.2%, respectively, no further progression rates 48.7% and 45.5%, respectively, and deterioration rates 12.8% and 10.4%, respectively (P = .44). Ambulatory rates at 1 month were 71.8% and 74.0%, respectively (P = .86). At other times after RT, the results were also not significantly different. Six-month local progressionfree survival was 75.2% after 4 Gy × 5 and 81.8% after 3 Gy × 10 (P = .51); 6-month overall survival was 42.3% and 37.8% (P = .68). Conclusion Short-course RT with 4 Gy35 was not significantly inferior to 3 Gy310 in patients with MESCC and poor to intermediate expected survival.
AB - Purpose To compare short-course radiotherapy (RT) (4 Gy × 5) to longer-course RT (3 Gy × 10) for metastatic epidural spinal cord compression (MESCC). Patients and Methods Two-hundred three patients with MESCC and poor to intermediate expected survival were randomly assigned to 4 Gy × 5 in 1 week (n = 101) or 3 Gy × 10 in 2 weeks (n = 102). Patients were stratified according to ambulatory status, time developing motor deficits, and primary tumor type. Seventyeight and 77 patients, respectively, were evaluable for the primary end point, 1-month overall response regarding motor function defined as improvement or no further progression of motor deficits. Other study end points included ambulatory status, local progression-free survival, and overall survival. End points were evaluated immediately after RT and at 1, 3, and 6 months thereafter. Results At 1 month, overall response rates regarding motor function were 87.2% after 4 Gy × 5 and 89.6% after 3 Gy × 10 (P = .73). Improvement rates were 38.5% and 44.2%, respectively, no further progression rates 48.7% and 45.5%, respectively, and deterioration rates 12.8% and 10.4%, respectively (P = .44). Ambulatory rates at 1 month were 71.8% and 74.0%, respectively (P = .86). At other times after RT, the results were also not significantly different. Six-month local progressionfree survival was 75.2% after 4 Gy × 5 and 81.8% after 3 Gy × 10 (P = .51); 6-month overall survival was 42.3% and 37.8% (P = .68). Conclusion Short-course RT with 4 Gy35 was not significantly inferior to 3 Gy310 in patients with MESCC and poor to intermediate expected survival.
UR - http://www.scopus.com/inward/record.url?scp=84964197184&partnerID=8YFLogxK
U2 - 10.1200/JCO.2015.64.0862
DO - 10.1200/JCO.2015.64.0862
M3 - Journal articles
C2 - 26729431
AN - SCOPUS:84964197184
SN - 0732-183X
VL - 34
SP - 597
EP - 602
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 6
ER -